The newly released annual drug review report for 2024 from China’s Center for Drug Evaluation (CDE) shows the center approved a total of 45 innovative small molecules and biologics last year, of which 17 (38%), 11 (24%) and 13 (29%) were approved via priority review, conditional or breakthrough therapy designation (BTD) pathways, respectively.
China Approvals Rise But Conditional-To-Full Conversion Slips
Oncology Still Top For Drugs, Biologics
A new annual report from China's CDE shows a rise in overall product approvals but a fall in the transition rate for conditional to full approvals, possibly signalling more stringent requirements.
Read more by Xu Hu
More from China
More from Pink Sheet
• By
Pink Sheet reporter and editors discuss how staff may not be the only thing the FDA could lose with the latest layoffs announced by the Health and Human Services Department.
• By
The European Medicines Agency has recommended five drugs for EU-wide approval , including Averoa’s Xoanacyl for concomitant hyperphosphatemia. Two companies have withdrawn their marketing authorization applications.
• By
Eli Lilly’ will request a re-examination after the European Medicines Agency declined to recommend its Alzheimer’s disease drug Kisunla for EU approval.